News List
Insomnia and schizophrenia innovative treatments approved
2020-02-04
Dayvigo (lembroexant) developed by Eisai is an orexin receptor antagonist. Orexin is a neuropeptide secreted by the hypo
First oral small molecule CGRP receptor inhibitor approved today for the treatment of migraine
2020-01-10
Recently, the US FDA announced that it has approved the listing of the calcitonin gene-related peptide (CGRP) receptor a
Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
2019-12-21
Novartis recently announced topline results from its pivotal global Phase III LUSTER-11and LUSTER-22studies that explore
Roche T + A immunotherapy research achieves historic breakthrough
2019-12-12
November 22, 2019, Roche announces data from positive studies of the IMbrave 150 phase III clinical trial aimed at treat
Hansoh pharm's first sorts of new medicine "Flumatinib" will be approved for listing
2019-11-20
Flumatinib is a tyrosine kinase inhibitor and it’s a second-generation TK inhibitor drug against Bcr-Abl that is intende
FDA approves Lilly Reyvow
2019-10-21
Recently, Lilly announced that the US FDA approved the company's development of Reyvow (lasmiditan) tablets, as a tr
The third anti-tb drug was approved by the FDA
2019-09-24
On August 14th, the FDA approved TB Alliance new fluorine-containing anti-tuberculosis drug Pretomanid to form BPaL with
Holiday Notice of Mid-Autumn Festival
2019-09-11
To all departments and all employees:According to the related provisions on national holidays & the actual situation
CPhI North America 2020 in Philadelphia USA Booth#1506
2019-08-26
FluoroPharm will exhibit CPhI North America 2020 in Pennsylvania Convention Center,Philadelphia, PA, USA, May 5-7,2020.O
FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor
2019-08-19
The U.S. Food and Drug Administration today granted accelerated approval to Rozlytrek (entrectinib), a treatment for adu